| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.912786 |
| 003 | CaOODSP |
| 005 | 20251003141204 |
| 006 | m o d f |
| 007 | cr mn||||||||| |
| 008 | 220627e202208 onc ob f000 0 eng d |
| 020 | |a9780660442617 |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 043 | |an-cn--- |
| 086 | 1 |aH164-277/2022E-PDF |
| 245 | 00|aGuidance document : |bthe management of drug submissions and applications. |
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada,|cAugust 2022. |
| 264 | 4|c©2022 |
| 300 | |a1 online resource (74 pages) |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |aIssued also in French under title: Ligne directrice : gestion des présentations et des demandes de drogues. |
| 500 | |a"Pub.: 220295." |
| 500 | |aIssued also in HTML format. |
| 504 | |aIncludes bibliographical references. |
| 650 | 0|aDrug approval|zCanada. |
| 650 | 0|aPharmaceutical policy|zCanada. |
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
| 775 | 08|tLigne directrice : |w(CaOODSP)9.912785 |
| 794 | |tGuidance document : |b2025|w(CaOODSP)9.945564 |
| 795 | |tGuidance document : |w(CaOODSP)9.901130 |
| 856 | 40|qPDF|s676 KB|uhttps://publications.gc.ca/collections/collection_2022/sc-hc/H164-277-2022-eng.pdf |
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/management-drug-submissions/industry/document.html |
| 986 | |a220295 |